NIVI

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023

Retrieved on: 
Wednesday, March 6, 2024
Novo Nordisk Foundation, Research, Biotechnology, DKK, Antimalarial medication, Education, Investment, Food, Partnership, NIVI, Vaccine, University, Health, Climate change, Novo Holdings A/S, CO2, Protein, Tuberculosis, Science, Agriculture, Bill, Human

In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.

Key Points: 
  • In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.
  • One of its largest mission-driven initiatives in 2023 was the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), a research and vaccine development initiative launched in partnership with the University of Copenhagen.
  • The DKK 9.1 billion awarded in 2023 marks an increase in grant giving from previous years.
  • The Novo Nordisk Foundation Cellerator, a world-class facility for developing and upscaling cell therapies for testing in humans.

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023

Retrieved on: 
Wednesday, March 6, 2024
Novo Nordisk Foundation, Research, Biotechnology, DKK, Antimalarial medication, Education, Investment, Food, Partnership, NIVI, Vaccine, University, Health, Climate change, Novo Holdings A/S, CO2, Protein, Tuberculosis, Science, Agriculture, Bill, Human

In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.

Key Points: 
  • In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.
  • One of its largest mission-driven initiatives in 2023 was the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), a research and vaccine development initiative launched in partnership with the University of Copenhagen.
  • The DKK 9.1 billion awarded in 2023 marks an increase in grant giving from previous years.
  • The Novo Nordisk Foundation Cellerator, a world-class facility for developing and upscaling cell therapies for testing in humans.

Major new vaccines initiative aims to fight deadly airborne infections

Retrieved on: 
Monday, December 18, 2023
Novo Nordisk Foundation, SSI, Research, Senior, Nasal spray, Disease, Statens Serum Institut, History, Faculty, University of Copenhagen, Immunology, Death, Vaccine, Science, GAS, Influenza, Medicine, University, Infection, Human, Partnership, DKK, Interior, Streptococcus, COVID-19 vaccine, Respiratory system, Microbiology, COVID-19, Knowledge, Life, Tuberculosis, Public, TB, Pharmaceutical industry, Management, Immunity, NIVI, Health

The aim is to create new or improved vaccines for some of the deadliest respiratory diseases, including tuberculosis (TB) and influenza.

Key Points: 
  • The aim is to create new or improved vaccines for some of the deadliest respiratory diseases, including tuberculosis (TB) and influenza.
  • Developed in partnership with the University of Copenhagen, it is the first vaccines initiative globally to focus solely on understanding how to generate immunity in the airway itself.
  • "The development of the Covid-19 vaccines demonstrated the extraordinary possibilities when interdisciplinary vaccine research and development are prioritised," says Krogsgaard Thomsen.
  • "We hope that NIVI's work can help prepare us for the next pandemic or even help consign airborne epidemics to history."

Major new vaccines initiative aims to fight deadly airborne infections

Retrieved on: 
Monday, December 18, 2023
Novo Nordisk Foundation, SSI, Research, Senior, Nasal spray, Disease, Statens Serum Institut, History, Faculty, University of Copenhagen, Immunology, Death, Vaccine, Science, GAS, Influenza, Medicine, University, Infection, Human, Partnership, DKK, Interior, Streptococcus, COVID-19 vaccine, Respiratory system, Microbiology, COVID-19, Knowledge, Life, Tuberculosis, Public, TB, Pharmaceutical industry, Management, Immunity, NIVI, Health

The aim is to create new or improved vaccines for some of the deadliest respiratory diseases, including tuberculosis (TB) and influenza.

Key Points: 
  • The aim is to create new or improved vaccines for some of the deadliest respiratory diseases, including tuberculosis (TB) and influenza.
  • Developed in partnership with the University of Copenhagen, it is the first vaccines initiative globally to focus solely on understanding how to generate immunity in the airway itself.
  • "The development of the Covid-19 vaccines demonstrated the extraordinary possibilities when interdisciplinary vaccine research and development are prioritised," says Krogsgaard Thomsen.
  • "We hope that NIVI's work can help prepare us for the next pandemic or even help consign airborne epidemics to history."